Development Genotoxicity Genotype Marketing 
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.
The Pharma Data
APRIL 7, 2021
Today’s approval is the culmination of a multi-year development program and validates the clinical benefit of this important treatment in metastatic TNBC,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Trodelvy Boxed Warning.
Expert insights. Personalized for you.
52 
Let's personalize your content